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Abstract    
Objective: Light chains kappa (κ) and lambda (λ) are immunoglobulin constituents but also 
circulate independently in blood as free light chains (FLC). We investigated whether a 
concomitant abnormality in FLC and immunoglobulin levels could identify a high risk of death 
sepsis subpopulation to inform future IVIg trials. We tested whether light chain allelic inclusion 
occurs in circulating B cells. 
Design: Prospective cohort study 
Setting: Adult general intensive care units (ICU) 
Patients: Adult sepsis patients without any documented immune comorbidity. 
Interventions: None 
Measurements and main results: Serum total FLC, IgG, IgA and IgM were measured on 
ICU Days 1, 3 and 7. Population normal ranges defined normal and abnormal categories. 
Logistic regression models tested any independent relationship between high-FLC, 
immunoglobulins and hospital mortality. CD19 B cell subsets expressing cell surface κ and λ 
were quantified by flow cytometry; their frequencies were compared against healthy subjects 
and correlation assessed against FLC concentrations. On ICU Day 1, high-FLCλ and high-
FLCκ were seen in 46.5% and 75.3% of the study cohort (n=101). Low immunoglobulin levels 
were commonplace (45.5%) on ICU admission. ICU admission day FLC and immunoglobulin 
concentrations were significantly correlated. Septic patients had significantly more CD19 B 
cells expressing both κ and λ compared with healthy controls (median (IQR) 4.1% (2.4, 11.0) 
vs. 1.3% (1.2, 2.9) respectively; p=0.0001); these correlated with FLC concentrations. 
Conclusions: To our knowledge, abnormalities and associations of FLC in critically ill adults 
with sepsis have not been previously reported. The additional prognostic value of FLCλ and 
the significance of allelic inclusion in B cells in sepsis require further investigation. 
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Introduction	
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host 
response to infection (1). Attempts to favorably modulate a dysregulated immune response 
with intravenous immunoglobulin therapy (IVIg) failed to improve outcomes, as these trials 
potentially did not target treatment responsive subpopulations (2-4). Studies that help to 
enrich sepsis subpopulations based on abnormalities in immunoglobulin biology could inform 
future IVIg trial design, as new trials are being planned (5). We recently tested whether low 
immunoglobulin G (IgG) levels on the day of sepsis diagnosis identified a higher risk of death 
subpopulation (6). Despite a high prevalence of low IgG levels, this abnormality alone did not 
identify mortality risk.  
 
In health, circulating immunoglobulin consists of heavy chains bound by disulfide bonds to 
either kappa (κ) or lambda (λ) light chains. These light chains are also measurable as 
circulating free light chains (FLC), separate from immunoglobulin molecules. Raised FLC 
levels are associated with sepsis risk factors such as low-grade inflammation, increasing age 
and renal dysfunction (7-9).  Altered FLC concentrations have been reported in a pilot study 
performed on 21 ICU patients with sepsis (10).   
 
Since reduced immunoglobulin and raised FLC concentrations are both associated with 
sepsis, we investigated whether their concomitant abnormality could enrich a sepsis 
population for IVIg trials (Table 1) (11, 12). Ideally, enrichment markers should forecast the 
likely patient outcome irrespective of baseline risk, and should also have biological plausibility 
(6, 11). Several observations highlight such plausibility for concomitant FLC and 
immunoglobulin abnormalities in sepsis, in addition to the known associations of FLCs 
described above (7-10).  In health, excess light chains are present in the perinuclear space to 
prevent intracellular heavy chain aggregation prior to immunoglobulin assembly, and are 
secreted as FLC after immunoglobulin assembly (13). Thus, impaired immunoglobulin 
assembly in sepsis could result in raised FLC and low immunoglobulin levels (2, 3, 14). We 
also considered whether an altered stoichiometry of light chain production could contribute to 
raised FLC concentrations.  Rules of allelic exclusion permit only a single immunoglobulin 
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specificity by each B cell.  However, we recently reported that acute inflammation in 
autoimmune diseases can result in simultaneous expression of both κ and λ light chains by a 
single B cell. Thus, light chain allelic inclusion in the context of acute inflammation may result 
in production of excess FLC (15). Against this background, after describing longitudinal 
changes in FLC and immunoglobulin levels in sepsis, we tested whether concomitant 
abnormalities in FLC and immunoglobulin levels on ICU admission day are independently 
associated with hospital mortality. We also examined surface κ and λ LC expression on B 
cells. 
 
Materials and Methods	
Study design and setting 
This prospective observational cohort study was performed in the general medical-
surgical ICUs of an university hospital.  Ethics committee approval was obtained prior to start 
of recruitment (10/H0807/81 and 12/LO/0326; Camberwell St Giles Committee, London, UK). 
Clinical management was at the discretion of the attending physician. 
 
Study population 
Consecutive patients with sepsis within the first 12 hours following ICU admission 
between 05/2011 and 01/2015 were included. Sepsis was identified using the old definition as 
evidence of two or more systemic inflammatory response syndrome (SIRS) criteria, with 
proven or suspected infection and at least one organ system dysfunction (cardiovascular, 
respiratory, renal, hematologic or metabolic) (16). Exclusion criteria included patients <18 
years, those with congenital hypogammaglobulinemia, known protein-losing enteropathies, 
nephrotic syndrome, neoplastic or proliferative hematologic diseases; those having received 
IVIg therapy in the last 3 months; those receiving high-dose corticosteroid therapy; ongoing 
blood loss (defined by blood transfusion requirement > 2 units/24 hour period); retroviral 
disease; and immune dysfunction as defined by Acute Physiology and Chronic Health 
Evaluation (APACHE) II score co-morbidities (17). We have recently published other details 
on B cell changes in sepsis from this population, using the same cohort (14). 
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Clinical data, blood sampling and flow cytometry 	
Baseline demographic data, infection details, and variables to record SIRS, APACHE II (17) 
and Sepsis-related Organ Failure Assessment (SOFA) scores (18) were collected.  Blood 
samples were collected within 12 hours of ICU entry on admission day (D1), on day 3 (D3), 
and on day 7 (or on the day of demise or discharge if these events occurred earlier). After 
clot separation and centrifugation (3000 rpm; 10 minutes; 4°C), serum samples were stored 
at -70°C. Blinded batch analysis was performed for immunoglobulin and FLC levels to reduce 
inter-assay variation. Immunoglobulin molecules (total IgG, IgA and IgM) (Dade Behring 
Nephelometer, Marburg, Germany) and serum FLC using polyclonal sheep antisera 
(Freelite™, Binding Site, Birmingham, UK) were analysed on a SPA plus analyser (Binding 
Site). The free light chain ratio (FLCR) was derived as the ratio of FLCκ to FLCλ.  
 
Flow cytometry was used to ascertain light chain allelic inclusion in circulating B cells using a 
Canto-A flow cytometer (Becton Dickinson (BD), Franklin Lakes, New Jersey). PBMCs were 
isolated within 4 hours of blood sampling using Ficoll density centrifugation. Anti-human 
antibodies, clone and company are reported in parenthesis. Anti-CD19 (PerCP Cy5.5; HB19; 
BD); anti-κ LC (ACP-H7; G20-193; BD); anti-λ LC (Pacific Blue; MHL-38; BioLegend) and 
Live/Dead Fixable Aqua (Life Technologies) antibodies were used for cell surface expression 
of CD19, LC-κ and LC-λ, respectively. Gating during analysis of flow cytometry standard 
(FCS) files were achieved using isotype controls, fluorescence minus-one controls, and/or 
single stain controls.  
 
Derivation of abnormal categories	
The reference normal ranges for an adult general population in the UK are IgG (6.1 – 16.2) 
g/l, IgA (0.8 – 5.0) g/l, IgM (0.4 – 2.4) g/l, FLCλ (5.7 – 26.3) mg/l, FLCκ (3.3 – 19.4) mg/l and 
FLCR (0.26 – 1.65). The upper and lower limits of these normal ranges were used to define 
normal and abnormal categories. These categorizations allowed generation of prevalence 
data, and comparison of the proportions of survivor and non-survivor sepsis patients with 
each abnormality. 
	 6	
Sample size estimation 
Sample size was estimated using precision estimates for IgG distribution (19), as IgG is the 
most often altered immunoglobulin in sepsis (6). One hundred patients were required to 
achieve a margin of error of 0.74 g/L of IgG measurement based on the population standard 
deviation of 3.72 g/L observed in the first 30 patients enrolled. 
 
Statistics 
Continuous data are presented as mean and standard deviation (SD) when normally 
distributed, and as median and interquartile range (IQR) when not. Frequency and 
percentages are presented for categorical data.  
 
Two sets of comparisons described longitudinal changes in FLC. First, we compared 
proportions of high FLCs and concentrations of FLCs between survivors and non-survivors on 
days 1, 3 and 7. Second, we compared how proportions of high FLCs and temporal changes 
in concentration varied between survivors and non-survivors using paired tests. A similar 
approach was used to describe changes in immunoglobulins.  
 
To report univariate associations and to inform logistic regression models, a pairwise 
correlation matrix was generated for admission day FLC, FLCR, IgG, IgA, IgM, white cell 
count, C-reactive protein (CRP), total SOFA and APACHE II score. Bonferroni corrections 
were performed for multiple comparisons. Two analyses were performed to assess any 
association between a concomitant admission day immunoglobulin and FLC abnormality and 
mortality. Stratified analyses were performed as shown in Table 1. Two logistic regression 
models were then used with acute hospital mortality as the outcome: model 1 had high-FLCλ, 
total APACHE II score, hypo-IgG, and hypo-IgM as binary covariates, while model 2 had high-
FLCκ, total APACHE II score, hypo-IgG, and hypo-IgM as binary covariates. 
 
B cell subsets are reported as a proportion of the live CD19 positive B cell population.  
Proportions were compared between healthly controls and sepsis. All analyses were 
performed using GraphPad Prism version 6.00 (GraphPad Software, La Jolla, CA, 
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www.graphpad.com) and/or Stata/SE Version 13.0 (StataCorp LP, College Station, TX). 
Reported p values are two sided with p values <0.05 representing statistical significance.  
 
Results 	
Study cohort 
Cohort characteristics by hospital survival status are summarized in Table 2. Acute hospital 
mortality was 26.7%. Non-survivors were older and had greater illness severity as evidenced 
by greater APACHE II and SOFA scores. The respiratory tract was the commonest infection 
site in both survivors and non-survivors. In two patients, the site of infection could not be 
confirmed.  
 
Longitudinal changes in FLCκ and FLCλ 
The prevalence of high FLCκ was similar in survivors and non-survivors on D1 (p=0.45); D3 
(p=0.18) and DF (p=0.75). No significant differences were seen in corresponding FLCκ 
concentrations at any timepoint (Figure 1a). The proportion of sepsis patients with abnormal 
FLCλ was significantly higher in non-survivors only on D1 (74.1% vs. 36.5%; p=0.001) but not 
D3 (p=0.24) or DF (p=0.11). There was an increase in corresponding FLCλ concentrations 
over time in both survivors and non-survivors (p<0.05). However, when comparing FLCλ 
concentrations on days 1, 3 and DF between survivors and non-survivors, there were no 
differences at any time point (Figure 1b).  
 
Longitudinal changes in FLCR 
Despite recruiting septic patients without any documented immune comorbidity, 29.7% had a 
high FLCR. Prevalence was higher in survivors on D1 (36.5% vs 11.1%, p=0.01). This ratio 
decreased on D3 compared to D1 in both survivors and non-survivors (p<0.05; Figure 1c). 
Analyses restricted to patients with a normal FLCR showed that the proportion of patients 
with a high FLCλ was more common in non-survivors on D1 (75.0% vs. 40.4%; p=0.007) 
whereas the proportion with high FLCκ was similar between survivors and non-survivors 
(63.8% vs. 83.3%; p=0.11). 
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Longitudinal changes in immunoglobulin subtypes 
Although hypo-IgG was the most prevalent immunoglobulin abnormality, there was no 
difference in hypo-IgG by hospital survival status at D1 (p=0.22); D3 (p=0.92) and DF 
(p=0.07). The nadir for IgG was seen on D3. The fall in D3 in eventual non-survivors was 8 
times greater than that seen in survivors (median (IQR) in survivors was -0.121 (-1.28; 0.87) 
and in non-survivors was -0.80 (-1.28; -0.3); p= 0.02). Compared to D1, D7 IgG 
concentrations rose only in survivors (p=0.004; Figure 1d). Similar to IgG concentrations, 
there were no difference in hypo-IgM by hospital survival status at any time point.  
The nadir for IgM was on D3, (p=0.02 in non-survivors; Figure 1e). Hypo-IgA was the least 
prevalent (6.9%) and observed in only 7 survivors (Figure 1f).  
 
Associations of FLC and immunoglobulin 
FLCκ was significantly correlated with FLCλ, FLCR, IgG and serum creatinine. FLCλ was 
significantly correlated with FLCκ, IgG, IgA and serum creatinine. IgG and IgM were 
significantly correlated. FLCs were not correlated to markers of illness severity (APACHE II 
and SOFA) nor to acute inflammation (CRP and WBC) (eFigure 1). 
 
High FLCλ is associated with mortality  
Using the concept presented in Table 1, the stratified analyses highlighted higher mortality 
only in patients with high FLCλ, irrespective of their hypo-IgG or hypo-IgM status (Figure 2a 
and Table-3). Hypo-IgA was not included in our logistic regression models assessing high 
FLC mortality relationship as it occurred only in survivors on Day 1. APACHE II score 
accounted for illness severity and differences in age between survivors and non-survivors 
reported in Table 2. In model 1, hospital mortality was significantly associated with the 
APACHE II score and high FLCλ. The increase in OR (95% CI) for hospital mortality per unit 
increase in APACHE II score was 1.2 (1.1 – 1.4; p<0.001) and 4.0 (1.3–12.4) for high FLCλ 
(p=0.017). In model 2, hospital mortality was significantly associated only with the APACHE II 
score; the OR (95% CI) per unit increase in APACHE II score was 1.2 (1.1–1.4; p<0.001) 
(eFigure2).    
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Allelic inclusion in B cells and associations 
The gating strategy for identification of light chain allelic inclusion is shown in eFIgure3. The 
characteristics of the 21 sepsis patient samples used for flow cytometry are summarized in 
eTable1. CD19 B cells expressing cell surface LCκ or LCλ, expressed as a proportion of alive 
CD19 population and as a ratio of CD19κ to CD19λ were similar in sepsis patients and 
healthy controls. Septic patients had a significantly higher proportion of CD19 B cells 
expressing both LCκ and LCλ (CD19κλ) than B cells taken from healthy subjects (median 
(IQR) 4.1% (2.4, 11.0) vs. 1.3% (1.2, 2.9) respectively; p=0.0001; Figure2b). A significant 
correlation existed between the frequencies of these CD19κλ cells and the corresponding FLC 
concentrations (Figure 2c). A significant correlation was only observed between FLCλ and 
CD19 B cells expressing cell surface LCλ (Figure 2c). 	
Discussion	
High FLCκ, high FLCλ and high FLCR are common in septic patients admitted to 
critical care without known immune comorbidities. The presence of a high FLCλ increases the 
risk of death, even after adjusting for APACHE II score, despite high FLCκ being the more 
common abnormality. The combination of high FLC and low immunoglobulins on ICU 
admission day was more prevalent in a greater proportion of non-survivors. Consistent with 
the published literature (6), we found that hypo-IgG and hypo-IgM were common in sepsis on 
D1, reaching a nadir on D3, and that more survivors incremented immunoglobulin levels over 
time. These findings increase the external validity of our results.  
 
The approach presented in Table-1 is discussed in the context of our results to inform 
trial design. IVIg treatment potentially restores normal serum immunoglobulin concentrations 
in patients with low IgG levels, in addition to contributing to immunomodulation (3). In clinical 
trials, the IVIg treatment effect will vary by the baseline risk of death, i.e. a heterogeneity in 
treatment effect (20, 21). Thus, enriching sepsis patients with a higher risk of death 
concomitant with a greater likelihood of treatment response inferred by low immunoglobulins 
on admission may be more likely to result in a positive outcome if the strategy is indeed 
effective (11, 12). In this study, we position FLCλ as a potential biomarker within the causal 
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pathway from immunoglobulin alterations to death in sepsis patients, after accounting for 
illness severity. High FLCλ identifies a higher risk of death sepsis population. The prevalence 
of high FLCλ within our sepsis cohort was 46.5%, with 74% of non-survivors having this 
abnormality. These concepts could be easily validated using data from ongoing trials (5). 
 
We observed major abnormalities in immunoglobulin levels without an increase in the 
risk of death; this finding is consistent with our previous systematic review (6). Dissecting the 
relative contributions of altered immunoglobulin production, impaired endothelial recycling, 
and immunoglobulin consumption for opsonization during sepsis is challenging due to the 
lack of a well characterized regulatory loop for immunoglobulin homeostasis (22). There are 
no mechanistic studies to date explaining immunoglobulin kinetics in sepsis. Our first novel 
finding is that FLCs are raised with a high FLCλ being associated with an increased risk of 
hospital mortality after adjustment for illness severity. The kidneys maintain circulating FLC 
homeostasis via glomerular clearance, proximal tubule endocytosis and catabolism (23). 
Impairments in renal function seen in sepsis could increase FLC concentrations, and this is 
supported by the positive correlation found between serum FLC and creatinine levels. The 
increase in FLC could also be due in part to impaired immunoglobulin assembly. A pilot study 
of 21 patients with pneumonia and septic shock found that FLC concentrations did not differ 
by IgG level (10). However, this study neither reported longitudinal changes in FLC by 
survival status, nor mechanisms. The FLCR was similar to our cohort, providing further 
external validity to our results (10).  
 
Important unanswered questions are the mechanisms by which FLC concentrations 
increase in sepsis, and how this affects sepsis biology in terms of illness severity or outcome. 
The increased proportion of CD19κλ dual cells in sepsis and their association with raised FLC 
concentrations is another novel finding that warrants further investigation. In healthy adults, 
CD19κλ dual cells represent only 0.5% of circulating B cells (24); the rise seen in our sepsis 
cohort could be a random simultaneous rearrangement of both light chain loci, but is most 
likely to represent allelic inclusion due to impaired kappa deleting element (KDE) activity or a 
transient phase during light chain revision (24). 
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 There are several limitations to our study. We have not investigated mechanisms 
behind these novel findings. We cannot ascertain whether the FLC abnormalities were 
present before the onset of sepsis nor whether FLCs represent a risk factor for sepsis, or 
mortality irrespective of sepsis (8). We accounted for these challenges by studying patients 
without immune comorbidity and by showing the independent effect of high FLCλ on hospital 
mortality after adjusting for APACHE II score. These novel observations should be replicated 
in other sepsis cohorts.  
 
As FLC concentrations are linked to immunoglobulin assembly in the literature, our 
findings imply that this FLC-immunoglobulin relationship makes FLC a potential biomarker for 
simultaneous prognostic and predictive enrichment of sepsis patients for IVIg therapy trials 
(11). This hypothesis could be confirmed using samples from existing trial data (5). Further 
questions raised include the contribution of elevated FLC to renal dysfunction in sepsis, as 
observed in myeloma patients (23). Raised FLC levels could also contribute to the prolonged 
neutrophil life span in sepsis (25), acting through enhanced tyrosine phosphorylation (26). 
The mechanisms involved in B-cell allelic inclusion in sepsis needs exploring.  
 
Conclusions 
In a well-characterized cohort of critically ill adults with sepsis without any immune 
comorbidity, we report a high prevalence of FLC abnormalities associated with immunoglobulin 
subtype abnormalities and offering prognostic utility. We show evidence of light chain allelic 
inclusion in B cells. The roles in sepsis pathology and as a putative biomarker for IVIg therapy 
warrants further study. 
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Figure and Table Legends 
Table legends 
Table 1: Potential relationships between immunoglobulins and free light chains 
abnormalities in sepsis patients  
We have considered the observable scenarios depicting acute changes in FLC and 
immunoglobulin concentrations, their possible underlying biological explanations and FLC as 
a surrogate marker linked to immunoglobulin biology with potential to enrich or stratify sepsis 
patients (11) in intravenous immunoglobulin trials. The rationale for this approach and the 
hypothetical scenarios presented here is that FLC levels are considered a valid surrogate 
marker of immunoglobulin production and potentially related to outcome, which places FLC 
as a biomarker in the causal chain between sepsis, immunoglobulins and death. We tested 
four possible combinations of two variables FLC and immunoglobulins, categorised into 
normal and abnormal based on their normal clinical laboratory range. Low immunoglobulins in 
sepsis could represent excess immunoglobulin consumption or extravasation of 
immunoglobulins(27) or impaired IgG recycling(3), or a normal immunoglobulin consumption 
but with impaired immunoglobulin assembly due to B cell abnormalities in sepsis(14). High 
FLC in sepsis could be related to either excess production related to sepsis related 
inflammation or due to allelic inclusion of light chains in B cells(13, 15). Enrichment principles 
are further explored in these reviews (11, 12). Abbreviations: FLC – Free light chains; IVIg – 
intravenous immunoglobulins 
Table 2: Cohort characteristics 
Table shows the salient sepsis specific and generic case mix of study cohort. 1continuous 
data presented as mean and standard deviation when normally distributed; 2Categorical data- 
presented as number (proportion); 3continuous data presented as median and inter quartile 
range when not normally distributed. APACHE – Acute physiology and chronic health 
evaluation; WCC – white cell count; CRP – C-reactive protein; SOFA- Sequential organ 
failure assessment; LOS – Length of stay; FLC = free light chains; FLCR – Free light chain 
kappa/lambda ratio. IgG – immunoglobulin G; IgM – immunoglobulin M; IgA – immunoglobulin 
The admission day concentrations of immunoglobulins, FLC and FLCR are summarized  
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Table-3: Prevalence of different scenarios by survival status in the overall cohort 
Normal/raised FLC and normal/low immunoglobulin categories were derived as described 
under Derivation of abnormal categories section. Then for each of the scenarios described in 
table-1 the proportion of patients meeting each scenario within survivors and non-survivors 
were estimated. These analyses were performed as the prevalence of each scenario and 
their potential association to survival status will inform future trial design. As our study was 
powered using precision sample size estimation of Immunoglobulin G concentrations, no 
formal statistical tests were done for comparisons between groups. There were 27 non-
survivors in this cohort. Abbreviations: IgG – immunoglobulin G; IgM – immunoglobulin M; 
FLCκ = free light chain kappa; FLCλ = free light chain lambda 
 
Figure legends 
Figure 1: Changes in FLC and Immunoglobulins over time by survival status 
Scatter plots showing all data points and median (IQR). D1= ICU admission day, D3= third 
day following admission and DF=Final sampling day. The shaded regions in 1a, Ib and 1c 
represents high-FLC category and in 1d, 1e and 1f represent hypo-Ig category. Comparisons 
by survival status were done using t-tests and within survivors and non-survivors were done 
using paired t-tests or non-parametric equivalent. [1a] FLCκ showed no significant differences 
in high-FLCκ prevalence and in FLCκ concentrations over time. [1b] FLCλ showed significant 
differences in high-FLCλ prevalence between survivors and non-survivors on D1 (p=0.001). 
The FLCλ concentrations increased significantly over time in survivors and non-survivors.  
[1c] FLCR showed significant differences in high-FLCR prevalence between survivors and 
non-survivors on D1 (p=0.01); D3 (p=0.51) and DF (p=0.34) and that there was a significant 
drop in FLCR between D1 and D3 in both survivors and non-survivors. [1d] IgG showed no 
significant differences in hypo-IgG prevalence between survivors and non-survivors on D1 
(p=0.22); D3 (p=0.92) and DF (p=0.07). In survivors D1 vs. D3 was not significant (p=0.57). In 
non-survivors D1 vs. DF (p=0.82) and D3 vs. DF (p=0.44) were not significant. [1e] IgM 
showed no significant differences in hypo-IgM prevalence between survivors and non-
survivors on D1 (p=0.63); D3 (p=0.62) and DF (p=0.49). The survivors had a higher IgM by 
the DF when compared to D1 and D3 levels. The D3 IgM concentrations were significantly 
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lower than D1 only in non-survivors (p=0.02) vs. p=0.43 in survivors. [1f] On D1, seven 
survivors had hypo-IgA. The IgA concentrations were similar in survivors and non-survivors 
on D1, D3 and DF. In survivors D1 vs. D3 was not significant p=0.50. In non-survivors D1 vs. 
D3 (p=0.28), D1 vs. DF (p=0.82) and D3 vs. DF (p=0.57) were not significant.   
 
Figure 2: Stratified analyses of mortality by high-FLC and immunoglobulin status and 
Allelic inclusion in B cells in sepsis 
[2a] The prevalence of FLC and immunoglobulin abnormality and their association to hospital 
mortality are reported. These analyses show outcomes in the scenarios A = Normal FLC + 
Normal immunoglobulin; B = Normal FLC + Low immunoglobulins; C = High-FLC + Normal 
immunoglobulin and D = High-FLC + Low immunoglobulin; [2b] Scatter plot showing all data 
points, the mean and 95% confidence intervals. Mann-Whitney U tests were used to generate 
p values by comparing sepsis (n=21) and healthy samples (n=15). The proportions of CD19κλ 
expressing B cells were seen significantly more common in sepsis patients. SS – Sepsis; H – 
Healthy; κ– Igκ on CD19 cells; λ– Igλ on CD19 cells; CD19κλ– CD19 expressing both Igκ and 
Igλ on cell surface. [2c] Statistically significant positive correlation was seen between the 
proportion of CD19κλ dual B cells in sepsis patients and the corresponding admission day 
FLCλ and FLCκ concentrations. Statistically significant positive correlation was also seen 
between the proportion of CD19λ B cells in sepsis patients and the corresponding admission 
day FLCλ concentrations but not with CD19κ B cells and the corresponding FLCκ 
concentrations. We used linear regression to derive R2 when there was significant correlation. 	
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Table-1: Hypothetical relationships between measured concentrations of immunoglobulins and free light chains and enrichment for trial design 
 
Abnormality Normal immunoglobulin Low Immunoglobulin 
Normal FLC 
Scenario A 
 
Production and consumption of 
immunoglobulin light and heavy 
chains are in balanced equilibrium 
Scenario B 
 
Immunoglobulin consumption and/or 
loss exceeds assembly 
Raised FLC 
Scenario C 
 
Effective immunoglobulin assembly 
meets consumption and loss 
demands, but there is excess light 
chain production 
Scenario D 
 
Rapid immunoglobulin consumption 
and/or excessive loss with 
ineffective immunoglobulin assembly 
results in a large excess of light 
chain production 
 
Table-2: Admission day cohort characteristics 
Variable Survivors 
(N=74) 
Non-survivors 
(N=27) 
1Age years 62.3 (12.6) 71.9 (14.1) 
2Female n (%) 26 (35.1%) 12 (44.4%) 
1APACHE II Score 18.4 (4.9) 24.0 (5.6) 
2Infection site n (%) 
Respiratory  
Intra-abdominal 
Wound and Soft tissue 
Urosepsis 
Meningitis 
Osteomyelitis 
Unknown 
 
46 (62.2%) 
12 (16.2%) 
7 (9.5%) 
6 (8.1%) 
1 
1 
1 
 
19 (70.4%) 
3 (11.1%) 
3 (11.1%) 
1 (3.7%) 
- 
- 
1 
3WCC count 14.6 (9.9, 19.0) 13.6 (10.3, 21.8) 
3CRP 148 (74, 278) 131 (93, 248) 
3Total SOFA score 7 (5, 9) 8 (6, 11) 
3Immunoglobulin concentrations 
IgG g/l 
IgA g/l 
IgM g/l 
 
7.2 (4.7 – 10.2) 
2.3 (1.5 – 3.0) 
0.6 (0.4 – 0.8) 
 
8.0 (5.4 – 10.5) 
2.2 (1.6 – 3.2) 
0.7 (0.4 - 1.2) 
3Free light chain concentrations 
FLC-Lambda mg/l 
FLC-Kappa mg/l 
FLC Kappa/Lambda Ratio 
 
23.2 (15.8 – 36.3) 
33.2 (18.6 – 54.5) 
1.3 (1.0 – 1.8) 
 
29.6 (22.5 – 43.1) 
38.8 (26.8 – 55.5) 
1.2 (1.0 – 1.5) 
3ICU length of stay 7 (3,12) 12 (6,18) 
3Hospital length of stay 23 (14, 41) 13 (7, 18) 
 	
Table-3: Prevalence of different scenarios by survival status in the overall cohort 
 
Parameter Normal IgG (N=65) 
Survivors vs non-survivors 
Reported as % 
Low IgG (N=36) 
Survivors vs non-survivors 
Reported as % 
Normal IgM (N=75) 
Survivors vs non-survivors 
Reported as % 
Low IgM (N=26) 
Survivors vs non-survivors 
Reported as % 
FLCλ 
category 
Normal FLCλ 
(N=54) 31.1% vs 14.8% 32.4% vs 11.1% 44.6% vs 18.5% 18.9% vs 7.4% 
High-FLCλ 
(N=47) 29.7% vs 59.3% 6.8% vs 14.8% 28.4% vs 59.3% 8.1% vs 14.8% 
FLCκ 
category 
Normal FLCκ 
(N=25) 12.2% vs 7.4% 14.9% vs 11.1% 14.8% vs 11.1% 11.1% vs 12.2% 
High-FLCκ 
(N=76) 48.7% vs 66.7% 24.3% vs 14.8% 58.1% vs 66.7% 14.8% vs 14.9% 
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eFigure-1: Pairwise correlation matrix  
Figure shows pairwise correlation matrix for FLCκ, FLCλ, FLCR, IgG, IgA, IgM, inflammation 
markers (C reactive protein (CRP), WCC (White cell count), creatinine and severity of illness 
using (APACHE II score (APII) and total sepsis related organ dysfunction assessment score 
(tSOFA). This analysis reports the Pearson’s product-moment correlation between the 
variables after accounting for multiple testing using Bonferroni’s correction. The p-values are 
presented in grey boxes above and the correlation coefficients are presented in the blue 
boxes below the blacked out diagonal cells. P values<0.05 were considered statistically 
significant. Only significant p-values are reported for clarity, and the corresponding correlation 
coefficient are highlighted in bold. 
 
eFigure-2: Logistic regression model assessing the relationship between FLC and 
acute hospital mortality.  
To test the interrelationship between admission day FLC and immunoglobulins to acute 
hospital mortality, we used two logistic regression models with acute hospital mortality as the 
outcome: model-1 had high-FLCλ, total APACHE II score, hypo-IgG, and hypo-IgM as binary 
covariates and model-2 had high-FLCκ, total APACHE II score, hypo-IgG, and hypo-IgM as 
covariates. 
 
e-Figure3: Gating strategy to identify B cells with kappa and lambda surface 
expression. 
Following identification of lymphocytes, a single cell gate was applied. This was followed by 
CD19 (Percp Cy5.5) vs. live-dead gate (amcyan). The alive CD19 population was then re-
gated using lambda (pacific-blue on x axis) and kappa (APC Cy7 on y-axis). To check 
whether non-specific binding of kappa and lambda fluorochromes were responsible for the 
dual kappa-lambda positive cells, the CD19 negative alive population was re-gated using 
lambda (pacific-blue on x axis) and kappa (APC Cy7 on y-axis). The cut offs for the kappa 
and lambda gates were ascertained by isotype controls as shown. 
 
eTable-1: Admission day characteristics of patients with sepsis where allelic inclusion 
in B cells were tested 
Abbreviations: M-male; F-female; WCC – Total White Cell Count; CRP – C – reactive protein; 
APACHE II score -Acute physiology and chronic health evaluation score; t-SOFA score – 
Total Sequential Organ Failure Assessment Score; ICU = Intensive Care Unit; CAP = 
community acquired pneumonia 
eFigure-1: Pairwise correlation matrix  
 
 FLCL FLCK FLCR IgG IgA IgM CRP WCC Creatinine APII tSOFA 
FLCL  <0.0001 NS <0.0001 0.03 NS NS NS <0.0001 NS NS 
FLCK 0.727  0.0009 <0.0001 NS NS NS NS <0.0001 NS NS 
FLCR -0.183 0.414  NS NS NS NS NS NS NS NS 
IgG 0.476 0.496 -0.017  NS 0.04 NS NS NS NS NS 
IgA 0.335 0.185 -0.200 0.300  NS NS NS NS NS NS 
IgM 0.076 0.076 -0.013 0.332 0.023  NS NS NS NS NS 
CRP -0.036 -0.091 -0.052 -0.077 -0.118 -0.028  NS NS NS NS 
WCC -0.063 0.013 0.078 0.242 0.104 0.244 0.185  NS NS NS 
Creatinine 0.469 0.581 0.255 0.130 0.042 -0.091 -0.023 -0.043  NS 0.01 
APII 0.137 0.143 0.061 0.094 0.195 -0.138 -0.033 0.184 0.212  <0.0001 
tSOFA 0.191 0.319 0.315 0.030 -0.053 -0.028 -0.180 -0.092 0.366 0.479  
 
eFigure-2: Logistic regression model assessing the relationship between FLC and 
acute hospital mortality 
 
 
 
 
 
 
-----------------------------------------------------------------------------------------------
------------------
      name:  <unnamed>
       log:  /Users/manushankar-hari/Documents/Research/PhD Papers/FLC paper/regression.
01_17.log
  log type:  text
 opened on:  10 Mar 2017, 12:40:13
. *** Model-1 - abnormal FLCL category
. logistic hosp_m APACHEII_Score IgGCAT IgMCAT FLCLCAT
Logistic regression                             Number of obs     =        101
                                                LR chi2(4)        =      27.99
                                                Prob > chi2       =     0.0000
Log likelihood = -44.642713                     Pseudo R2         =     0.2387
--------------------------------------------------------------------------------
        hosp_m | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
---------------+----------------------------------------------------------------
APACHEII_Score |   1.215561   .0653236     3.63   0.000     1.094042    1.350579
        IgGCAT |   .9231006   .5848797    -0.13   0.900     .2666397    3.195753
        IgMCAT |   .6464151   .4260445    -0.66   0.508     .1776212    2.352493
       FLCLCAT |   3.985089   2.308288     2.39   0.017     1.280547    12.40168
         _cons |   .0030006   .0038824    -4.49   0.000     .0002376    .0378922
--------------------------------------------------------------------------------
. *** Model-2 Abnormal FLCK category
. logistic hosp_m APACHEII_Score IgGCAT IgMCAT FLCKCAT
Logistic regression                             Number of obs     =        101
                                                LR chi2(4)        =      22.43
                                                Prob > chi2       =     0.0002
Log likelihood = -47.424497                     Pseudo R2         =     0.1912
--------------------------------------------------------------------------------
        hosp_m | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
---------------+----------------------------------------------------------------
APACHEII_Score |   1.226188   .0632714     3.95   0.000     1.108243    1.356685
        IgGCAT |   .6751069    .409152    -0.65   0.517     .2058247    2.214357
        IgMCAT |   .7062794   .4534791    -0.54   0.588     .2006539    2.486025
       FLCKCAT |   1.707432   1.164346     0.78   0.433     .4486266    6.498331
         _cons |   .0039778   .0054098    -4.06   0.000     .0002767    .0571853
--------------------------------------------------------------------------------
. log close
      name:  <unnamed>
       log:  /Users/manushankar-hari/Documents/Research/PhD Papers/FLC paper/regression.
01_17.log
  log type:  text
 closed on:  10 Mar 2017, 12:41:22
-----------------------------------------------------------------------------------------------
------------------
eFigure-3: Gating strategy to identify B cells with kappa and lambda surface expression 
 
 
 eTable-1: Admission day characteristics of patients with sepsis where allelic inclusion 
in B cells were tested 
Case Age 
year 
Sex Infection WCC 
103/µL 
CRP 
mg/L 
APACHE 
II score 
t-SOFA 
score 
Outcome 
CSII007 68 M CAP 26.3 176 21 8 Alive 
CSII008 71 M CAP 11.4 205 16 7 Alive 
CSII010 64 M Cellulitis of 
foot and CAP 
22 100 18 6 Alive 
CSII011 89 F CAP 17.4 87 15 7 Died 
CSII012 61 F CAP 27 25 19 10 Alive 
CSII013 51 F CAP 18.4 320 24 11 Alive 
CSII014 66 M CAP 1.9 90 17 10 Alive 
CSII020 44 M CAP 34.6 300 14 7 Alive 
CSII021 64 M CAP 11.6 32 27 7 Alive 
CSII023 74 M CAP 4 28 18 12 Alive 
CSII024 73 F Intra-
abdominal 
sepsis 
14.6 317 19 6 Alive 
CSII026 40 M CAP 22.6 234 18 3 Alive 
CSII031 47 F CAP 20.9 8 16 3 Alive 
CSII032 81 M CAP 8.6 161 26 9 Alive 
CSII033 18 M CAP 24.9 310 21 13 Alive 
CSII035 71 F Aspiration 
pneumonia 
23.9 170 27 9 Alive 
CSII037 43 F Urosepsis 12.5 511 13 5 Alive 
 
